Luspatercept and ESA-based regimens show higher rates of erythroid haematological improvement in lower-risk MDS
Different Medications Show Different Benefits for Myelodysplastic Syndromes
This systematic review and network meta-analysis of 20 trials involving 2,877 participants evaluated pharmacological treatments for lower-ri…
New research shows different medications offer varying benefits for patients with lower-risk myelodysplastic syndromes based on specific hea…
Roxadustat increases odds of vascular access thrombosis and all-cause mortality in patients with chronic kidney disease
Roxadustat Linked to Higher Risk of Blood Clots in Kidney Patients
This systematic review and meta-analysis of 11,418 adults with chronic kidney disease found that roxadustat is associated with higher odds o…
A review of over 11,000 patients suggests roxadustat may increase the risk of blood clots and death for those with chronic kidney disease.
Systematic review examines early erythropoiesis-stimulating agents for preterm infants across multiple clinical outcomes and safety endpoints
Early blood boosters may lower severe brain injury risk in premature babies
A systematic review of 37 trials involving 6,724 preterm or low-birthweight infants found that early erythropoiesis-stimulating agents likel…
A review of 37 studies suggests early blood boosters might lower severe brain injury and severe gut illness in premature infants without rai…
Systematic review and meta-analysis of erythropoiesis-stimulating agents in chronic heart failure and anaemia
New drugs help heart failure patients stay out of the hospital
This systematic review and meta-analysis evaluated erythropoiesis-stimulating agents (ESAs) in adults with chronic heart failure and anaemia…
A new review shows specific drugs can keep heart failure patients out of the hospital while improving their daily energy and movement.
VEXAS Syndrome Clinical Features and Treatment Outcomes in a Chinese Cohort of 16 Patients
Small study links UBA1 gene variants to blood and inflammatory issues in China
This retrospective cohort study of 16 Chinese patients describes main clinical features and treatment responses in VEXAS syndrome.
A specific genetic change called a UBA1 variant was found in 81 percent of patients in China with blood disorders and inflammation affecting…